Research Paper Volume 15, Issue 24 pp 14996—15024
ATRX is a predictive marker for endocrinotherapy and chemotherapy resistance in HER2-/HR+ breast cancer through the regulation of the AR, GLI3 and GATA2 transcriptional network
Figure 7. H3K9me3 ChIP-seq for normal breast epithelium tissue and MCF-7 in ENCODE. The signal intensities and peaks of H3K9me3 on ATRX (A), AR (B), GLI3 (C) and GATA2 (D) in normal breast epithelium tissues and 10 MCF-7 cells.